News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PARI Pharma Unveils Closed System Using eFlow Technology at Medical Plastics Conference



10/7/2008 9:22:11 AM

MONTEREY, Calif., Oct. 6 /PRNewswire/ -- Today, PARI Pharma GmbH will unveil a prototype Closed System using eFlow Technology that uses single dose ampoules to control medication used in the nebulizer system. By creating a proprietary, unit-dose ampoule that is required to operate the nebulizer, the Closed System using eFlow Technology meets an unmet need by reducing the risk of using the wrong medication in the delivery device, simplifying filling procedures, improving dose uniformity and hygiene.

"This is a very exciting period in inhalation drug development. Building on our ability to customize a delivery device and a medication formulation, we have been able to take eFlow Technology a step further by creating an aerosol device that will only deliver its matching formulation. This has a number of advantages for our pharmaceutical partners, physicians, and patients. The Closed System using eFlow Technology takes away the risk of someone putting anything other than their prescribed medication into an advanced delivery device, while keeping medication sealed until it is opened in the nebulizer," said Geoff A. Hunziker, president of eFlow LLC. "As new device technologies develop, it is critical for safety and efficacy to ensure patients use the approved delivery device for the inhaled drug."

Thomas Gallem, director of product design of PARI Pharma, will present "Development of a closed, ampoule-based electronic nebulizer system -- next step in drug-device combination for liquid aerosol therapy" at the 22nd Annual Medical Plastics Conference in Copenhagen, Denmark today.

PARI Pharma is currently in discussions about introducing the Closed System using eFlow Technology into new clinical development programs with pharmaceutical partners.

About eFlow Technology

eFlow Technology enables extremely efficient aerosolization of liquid medications via a vibrating, perforated membrane that includes thousands of small holes that produce the aerosol mist. Compared to other nebulization technologies, eFlow Technology produces aerosols with a very high density of active drug, a precisely defined droplet size, and a high proportion of respirable droplets delivered in the shortest possible period of time. Combined with its silent mode of operation, small size (it fits in the palm of your hand), light weight, and battery use, products incorporating eFlow Technology reduce the burden of taking daily, inhaled treatments. eFlow Technology and products based on it are proprietary to PARI Pharma.

PARI Pharma partners with pharmaceutical companies to develop new or improved therapies with eFlow Technology and other advanced delivery platforms. Investigational eFlow Nebulizer Systems are optimized per investigational drug product and are currently in clinical trials for asthma, cystic fibrosis, respiratory syncytial virus (RSV) infection, and treatments for lung transplant patients among other indications.

About PARI Pharma

PARI Pharma focuses on the development of aerosol delivery devices and therapies. Based on PARI's 100-year history working with aerosols, PARI Pharma develops treatments for pulmonary and nasal administration optimized with advanced delivery technologies, such as eFlow Technology.

PARI Pharma provides comprehensive inhalation drug development, including nebulizer formulation development and optimization, CMC, analytics, aerosol characterization, clinical protocol development, and regulatory guidance. PARI Pharma has several clinical development programs ongoing, either partnered or on its own. PARI Pharma, a PARI Medical Holding company, is located in Munich, Germany with a major presence in the United States. Online at http://www.paripharma.com

Additional information on eFlow Technology is available by contacting Kirsten Ayars at 805-452-7909 or Geoff A. Hunziker at 831-372-3580.

CONTACT: Kirsten Ayars, +1-805-452-7909, or Geoff A. Hunziker,
+1-831-372-3580, both for PARI Pharma GmbH

Web site: http://www.paripharma.com/


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES